trending Market Intelligence /marketintelligence/en/news-insights/trending/O_9pgk5mLA5Pw0w4D6wPmg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Stryker to buy Entellus Medical in $662M deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Stryker to buy Entellus Medical in $662M deal

Stryker Corp. agreed to buy medical device maker Entellus Medical, Inc. for an equity value of about $662 million.

Entellus Medical specializes in making minimally invasive devices for procedures related to ear, nose and throat, or ENT.

Under the deal, which would complement Stryker's existing ENT portfolio, the company would pay Entellus' shareholders $24 per share.

The closing of this transaction is subject to approval by Entellus' stockholders, expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions.

The deal is expected to be dilutive to Stryker's 2018 adjusted net earnings per diluted share by about 4 cents and accretive thereafter.

Guggenheim Securities acted as financial adviser and Skadden Arps Slate Meagher & Flom LLP served as outside legal counsel to Stryker for the deal.